Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study
ConclusionsOur results suggest that switching to macitentan in patients with PAH who discontinued bosentan/ambrisentan was well-tolerated and effective. Further studies are needed to confirm these observations.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Brain | Cardiology | Cardiovascular | Heart | Hypertension | International Medicine & Public Health | Neurology | Spain Health | Study | Transplants | WHO | Women